China biotech Innovent's recent success in raising $100 million in venture capital to help it build a pipeline of biosimilars could be a signal of how…

LabCorp is diversifying. The big diagnostics player has swooped in to buy the contract research organization Covance for $6.1 billion in cash and stock,…

Avillion has scored one of its first risk-sharing deals on a late-stage pharma asset, striking a deal to do a Phase III study of Pfizer's Bosulif (…

The Cranbury, NJ-based biotech says they will focus on knockoffs ofHumira, Rituxan, Avastin, Herceptin and Erbitux.

In the pact, investigators at Merck Serono will join hands with experts at Quintiles to shape and guide the company's R&D strategy while the…

PRACS Institute, the CRO that attempted to rise Phoenix-like from the ashes of scandal-plagued Cetero, has reportedly slammed its doors shut, laying off…

For years now Big Pharma companies have been pouring billions into ambitious new research efforts in China, anxious to capitalize on one of the world's…

Remember those rumors back in January about a big Quintiles IPO? Somebody had some good information. The global CRO filed its S-1 with the SEC this afternoon,…